News

Facing a critical shortage of N95 face masks that block the coronavirus, Duke Health research and clinical teams have confirmed a way to use existing vaporized hydrogen peroxide methods to decontaminate the masks so they can be reused.

Although most research laboratories at Duke University are shuttered to prevent future transmission of the Covid-19 coronavirus, one of the few to remain open houses a powerful machine that Duke researchers think will be instrumental in developing a vaccine for the virus.

Everything Duke experts have learned over the years about the spread of new diseases, the biology of viruses, and the techniques of developing treatments and vaccines is now being applied to the new coronavirus, SARS-CoV-2, and the illness it causes, COVID-19.

Duke University Hospital has joined the first national study to test a potential therapy for COVID-19, giving hospitalized adult patients with significant symptoms an option to participate.

A Duke University professor of medicine and global health has been studying emerging infections for his entire career but has yet to see anything capture the attention of society quite like this.

Officials at Duke, along with health officials worldwide, are monitoring an outbreak of pneumonia caused by a novel (new) coronavirus that originated in late 2019. We are not aware of any 2019 novel coronavirus (COVID-19) cases at any Duke campus or facility. We are providing this information to raise awareness and inform the Duke community.

As the coronavirus spreads, deaths mount and fears grow across the globe, biotech companies, universities and government agencies scramble – some together, others alone – for a vaccine to contain it.

When a Duke-led research team won a $300 million federal grant to help develop an AIDS vaccine in 2005, the global situation was looking grim.

An international commission of global experts convened by the International AIDS Society and The Lancet in 2018 advised that to eliminate HIV, global treatment efforts should be complemented by a robust scale-up in primary HIV prevention, including the development of a preventive vaccine.

The CDC’s Immunization Safety Office, Duke Human Vaccine Institute and Kaiser Permanente Vaccine Study Center conducted a clinical study, funded by the CDC’s Clinical Immunization Safety Assessment (CISA) Project, to assess whether the risk of fever, and potentially febrile seizure, might be reduced by administering the quadrivalent inactivated influenza vaccine (IIV4) separately from the pneumococcal (PCV13) and diphtheria-tetanus-pertussis (DTaP) vaccines.